Table 2.
Baseline clinical characteristics of patients.
| Study | Age (y) | Male (%) | EF (%) | No-ischemic (%) | NYHA (%) | Pharmacological therapy (%) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| II | III | ACEI/ARB | β-blocker | Amiodarone | Digoxin | |||||
| CAT | 52±11 | 83 | 24 | 100 | 67 | 33 | 94 | 4 | NR | 86 |
| AMIOVIRT | 59±11 | 72 | 23 | 100 | 35 | 25 | 85 | 52 | 50 | 71 |
| DEFINITE | 58 | 71 | 21 | 100 | 54 | 21 | 97 | 86 | 4 | 42 |
| SCD-HeFT | 60 | 77 | 25 | 47.3 | 71 | 29 | NR | 69 | NR | 67 |
| DNISH | 64±8 | 72 | 25 | 100 | 54 | 45 | 97 | 92 | 6 | NR |
ACE/ARB=angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; AMIOVIRT=Amiodarone vs. Implantable Defibrillator Randomized Trial; CAT=cardiomyopathy Trial; DANISH=Danish Study; DEFINITE=Defibrillators in non-Ischemic cardiomyopathy treatment evaluation; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association; SCD-HeFT=Sudden Cardiac Death in Heart Failure Trial